| |
| |
|
| Insider
Information: |
Kulkarni Samarth |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
208,122 |
|
|
Indirect Shares
|
200,000 |
|
|
| Direct
Value |
$12,605,950 |
|
|
|
Indirect Value
|
$12,114,000 |
|
|
| Total
Shares |
408,122 |
|
|
| Total
Value |
$24,719,950 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -45.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Crispr Therapeutics Ag |
CRSP |
|
2024-04-15 |
208,122 |
2024-04-15 |
200,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
113 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• – – |
2017-12-01 |
4 |
A |
$19.12 |
$509,873 |
D/D |
26,667 |
133,560 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Business Officer |
• – – |
2017-04-19 |
4 |
AS |
$17.54 |
$129,754 |
D/D |
(7,258) |
134,047 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Business Officer |
• – – |
2017-04-20 |
4 |
AS |
$17.36 |
$48,621 |
D/D |
(2,800) |
134,047 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Business Officer |
• – – |
2017-04-21 |
4 |
AS |
$17.01 |
$51,033 |
D/D |
(3,000) |
134,047 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Business Officer |
• – – |
2017-04-24 |
4 |
AS |
$16.46 |
$57,619 |
D/D |
(3,500) |
134,047 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Business Officer |
• – – |
2017-04-25 |
4 |
AS |
$16.87 |
$86,290 |
D/D |
(5,115) |
134,047 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Business Officer |
• – – |
2017-04-26 |
4 |
AS |
$16.74 |
$54,816 |
D/D |
(3,275) |
134,047 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Business Officer |
• – – |
2017-04-27 |
4 |
AS |
$16.78 |
$37,023 |
D/D |
(2,206) |
134,047 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Business Officer |
• – – |
2017-08-28 |
4 |
AS |
$20.09 |
$465,162 |
D/D |
(23,154) |
110,893 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Business Officer |
• – – |
2017-08-30 |
4 |
AS |
$20.00 |
$80,000 |
D/D |
(4,000) |
106,893 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2018-06-01 |
4 |
AS |
$67.28 |
$1,040,400 |
D/D |
(15,000) |
148,560 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2019-04-29 |
4 |
AS |
$42.03 |
$840,600 |
D/D |
(20,000) |
166,542 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2019-06-17 |
4 |
AS |
$46.00 |
$920,000 |
D/D |
(20,000) |
165,801 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2020-05-19 |
4 |
AS |
$65.16 |
$280,644 |
D/D |
(4,307) |
171,526 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2020-05-20 |
4 |
AS |
$65.28 |
$698,039 |
D/D |
(10,693) |
171,526 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2020-06-01 |
4 |
AS |
$63.57 |
$1,117,266 |
D/D |
(17,275) |
171,526 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2020-12-10 |
4 |
AS |
$141.17 |
$2,845,782 |
D/D |
(20,000) |
169,189 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2021-01-15 |
4 |
AS |
$211.83 |
$4,273,311 |
D/D |
(20,000) |
182,989 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2021-06-15 |
4 |
AS |
$125.39 |
$3,792,804 |
D/D |
(30,000) |
187,719 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2021-08-04 |
4 |
AS |
$125.02 |
$187,530 |
D/D |
(1,500) |
187,719 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2021-08-05 |
4 |
AS |
$126.67 |
$3,675,939 |
D/D |
(28,500) |
187,719 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2022-06-29 |
4 |
AS |
$61.42 |
$1,539,862 |
D/D |
(25,000) |
290,279 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2022-07-27 |
4 |
AS |
$75.64 |
$1,897,747 |
D/D |
(25,000) |
290,279 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2022-08-29 |
4 |
AS |
$66.14 |
$1,671,084 |
D/D |
(25,000) |
290,279 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Executive Officer |
• • – |
2022-09-28 |
4 |
AS |
$64.58 |
$1,615,160 |
D/D |
(25,000) |
290,279 |
0 |
% |
|
113 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
